Please use this identifier to cite or link to this item:
Title: COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020)
Author: Marín Jiménez, Ignacio
Zabana, Yamile
Rodríguez Lago, Iago
Marín, Laura
Barreiro de Acosta, Manuel
Esteve i Comas, Maria
Keywords: COVID-19
Colitis ulcerosa
Malaltia de Crohn
Ulcerative colitis
Crohn's disease
Issue Date: 15-May-2020
Publisher: Elsevier
Abstract: COVID-19 is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was described in China in late 2019. There are currently more than three million diagnosed cases, constituting a pandemic which has caused a worldwide crisis. The devastating effects of this infection are due to its highly contagious nature and although mild forms predominate, in absolute values, the rates for severe forms and mortality are very high. The information on the characteristics of the infection in inflammatory bowel disease is of special interest, as these patients have higher attendance at health centres, which may increase their risk of infection. Furthermore, the treatments used to control the inflammatory activity may modify the disease course of COVID-19. The Spanish Working Group on Crohn's Disease and Ulcerative Colitis and the Spanish Nurses Working Group on Inflammatory Bowel Disease have prepared this document as a practical response to some common questions about the treatment of these patients.
Note: Reproducció del document publicat a:
It is part of: Gastroenterologia y Hepatologia, 2020, vol. 43(7), num. 7, p. 408-413
Related resource:
ISSN: 0210-5705
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
704321.pdf501.64 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons